The inhibition of cholesteryl ester transfer protein: A long and winding road

Journal of Lipid Research

Volumn 53, Issue 6, 2012, Pages 1039-1041

  Rye, Kerry Anne ^a,b,c   Barter, Philip J ^a,b  

^a HEART RESEARCH INSTITUTE   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN ANTIBODY; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN ANTIBODY; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CETP GENE; CHOLESTEROL BLOOD LEVEL; DNA POLYMORPHISM; DRUG MECHANISM; DRUG TOLERABILITY; GENE; HEART PROTECTION; HETEROZYGOTE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MONOTHERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LIPID INTERACTION;

APOLIPOPROTEIN B-48; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; HUMANS; LIPOPROTEINS; MALE; TRIGLYCERIDES;

EID: 84861436289     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E027334     Document Type: Note

References (30)

1. Barter, P.J., and J.I. Lally. 1978. The activity of an esterified cholesterol transferring factor in human and rat serum. Biochim. Biophys. Acta. 531: 233-236. (Pubitemid 9056797)
2. Chajek, T., and C.J. Fielding. 1978. Isolation and characterization of a human serum cholesteryl ester transfer protein. Proc. Natl. Acad. Sci. USA. 75: 3445-3449. (Pubitemid 8395089)
3. Drayna, D., A.S. Jarnagin, J. McLean, W. Henzel, W. Kohr, C. Fielding, and R. Lawn. 1987. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature. 327: 632-634. (Pubitemid 17086900)
4. Kondo, I., K. Berg, D. Drayna, and R. Lawn. 1989. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels. Clin. Genet. 35: 49-56. (Pubitemid 19029791)
5. Thompson, A., E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R.P. Dullaart, B. Keavney, Z. Ye, and J. Danesh. 2008. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 299: 2777-2788. (Pubitemid 351846853)
6. Ridker, P.M., G. Pare, A.N. Parker, R.Y. Zee, J.P. Miletich, and D.I. Chasman. 2009. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2: 26-33.
7. Yamashita, S., D.Y. Hui, D.L. Sprecher, Y. Matsuzawa, N. Sakai, S. Tarui, D. Kaplan, J.R. Wetterau, and J.A. Harmony. 1990. Total deficiency of plasma cholesteryl ester transfer protein in subjects homozygous and heterozygous for the intron 14 splicing defect. Biochem. Biophys. Res. Commun. 170: 1346-1351. (Pubitemid 20273417)
8. Inazu, A., M.L. Brown, C.B. Hesler, L.B. Agellon, J. Koizumi, K. Takata, Y. Maruhama, H. Mabuchi, and A.R. Tall. 1990. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323: 1234-1238. (Pubitemid 20366528)
9. Ikewaki, K., M. Nishiwaki, T. Sakamoto, T. Ishikawa, T. Fairwell, L.A. Zech, M. Nagano, H. Nakamura, H.B. Brewer, Jr., and D.J. Rader. 1995. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J. Clin. Invest. 96: 1573-1581.
10. Di Angelantonio, E., N. Sarwar, P. Perry, S. Kaptoge, K.K. Ray, A. Thompson, A.M. Wood, S. Lewington, N. Sattar, and C.J. Packard, et al. 2009. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 302: 1993-2000.
11. Whitlock, M.E., T.L. Swenson, R. Ramakrishnan, M.T. Leonard, Y.L. Marcel, R.W. Milne, and A.R. Tall. 1989. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J. Clin. Invest. 84: 129-137. (Pubitemid 19170102)
12. Evans, G.F., W.R. Bensch, L.D. Apelgren, D. Bailey, R.F. Kauffman, T.F. Bumol, and S.H. Zuckerman. 1994. Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: effects on HDL subspecies, quantity, and apolipoprotein distribution. J. Lipid Res. 35: 1634-1645. (Pubitemid 24291224)
13. Sugano, M., N. Makino, S. Sawada, S. Otsuka, M. Watanabe, H. Okamoto, M. Kamada, and A. Mizushima. 1998. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273: 5033-5036. (Pubitemid 28108660)
14. Rittershaus, C.W., D.P. Miller, L.J. Thomas, M.D. Picard, C.M. Honan, C.D. Emmett, C.L. Pettey, H. Adari, R.A. Hammond, and D.T. Beattie, et al. 2000. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20: 2106-2112.
15. Okamoto, H., F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai. 2000. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406: 203-207. (Pubitemid 30469005)
16. Clark, R.W., R.B. Ruggeri, D. Cunningham, and M.J. Bamberger. 2006. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47: 537-552. (Pubitemid 43345595)
17. Clark, R.W., T.A. Sutfin, R.B. Ruggeri, A.T. Willauer, E.D. Sugarman, G. Magnus-Aryitey, P.G. Cosgrove, T.M. Sand, R.T. Wester, and J.A. Williams, et al. 2004. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24: 490-497. (Pubitemid 38326143)
18. Morehouse, L.A., E.D. Sugarman, P.A. Bourassa, T.M. Sand, F. Zimetti, F. Gao, G.H. Rothblat, and A.J. Milici. 2007. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. 48: 1263-1272. (Pubitemid 47312028)
19. Brousseau, M.E., E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Digenio, R.W. Clark, J.P. Mancuso, and D.J. Rader. 2004. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol . N. Engl. J. Med. 350: 1505-1515. (Pubitemid 38477775)
20. Millar, J.S., M.E. Brousseau, M.R. Diffenderfer, P.H. Barrett, F.K. Welty, A. Faruqi, M.L. Wolfe, C. Nartsupha, A.G. Digenio, and J.P. Mancuso, et al. 2006. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler. Thromb. Vasc. Biol. 26: 1350-1356. (Pubitemid 44305381)
21. McKenney, J.M., M.H. Davidson, C.L. Shear, and J.H. Revkin. 2006. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. 48: 1782-1790. (Pubitemid 44648632)
22. Barter, P.J., M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.C. Tardif, and D.D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122. (Pubitemid 350146106)
23. Nissen, S.E., J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, W.T. Duggan, W. Ruzyllo, W.B. Bachinsky, G.P. Lasala, and E.M. Tuzcu. 2007. Effect of torcetrapib on the progression of coronary atherosclerosis . N. Engl. J. Med. 356: 1304-1316. (Pubitemid 46513296)
24. Kastelein, J.J., S.I. van Leuven, L. Burgess, G.W. Evans, J.A. Kuivenhoven, P.J. Barter, J.H. Revkin, D.E. Grobbee, W.A. Riley, and C.L. Shear, et al. 2007. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356: 1620-1630. (Pubitemid 46631671)
25. Barter, P., and K.A. Rye. 2011. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? Trends Pharmacol. Sci. 32: 694-699.
26. Cannon, C.P., S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, A.M. Gotto, M. Stepanavage, S.X. Liu, P. Gibbons, and T.B. Ashraf, et al. 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363: 2406-2415.
27. Schwartz, G.G., A.G. Olsson, C.M. Ballantyne, P.J. Barter, I.M. Holme, D. Kallend, L.A. Leiter, E. Leitersdorf, J.J. McMurray, P.K. Shah, J.C. Tardif, B.R. Chaitman, R. Duttlinger-Maddux, and J. Mathieson. 2009. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 158: 896-901 e893.
28. Brousseau, M.E., M.R. Diffenderfer, J.S. Millar, C. Nartsupha, B.F. Asztalos, F.K. Welty, M.L. Wolfe, M. Rudling, I. Bjorkhem, and B. Angelin, et al. 2005. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25: 1057-1064. (Pubitemid 40627855)
29. Welty, F.K., A.H. Lichtenstein, P.H. Barrett, G.G. Dolnikowski, and E.J. Schaefer. 2004. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler. Thromb. Vasc. Biol. 24: 1703-1707. (Pubitemid 39180898)
30. Diffenderfer, M.R., M.E. Brousseau, J.S. Millar, P.H.R. Barrett, C. Nartsupha, P.M. Schaefer, M.L. Wolfe, G.G. Dolnikowski, D.J. Rader, and E.J. Schaefer. 2012. Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism. J. Lipid Res. 53: 1190-1199.